Vedanta Biosciences to Present at Upcoming Investor Conferences - April 29, 2024

2024-04-29

临床2期临床3期微生物疗法

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that members of its executive team will participate at the following investor conferences: Wells Fargo Virtual Private Biotech Symposium Date: Monday, May 6, 2024 Virtual 1x1 meetings only The Citizens JMP Life Sciences Conference Dates: May 13-14, 2024 Presentation: Tuesday, May 14 at 12:30 p.m. ET Location: New York Hilton Midtown, New York, NY About Vedanta Biosciences Vedanta Biosciences is a clinical-stage biopharmaceutical company developing medicines for the treatment of gastrointestinal diseases. The company’s lead assets are potential first-in-class oral therapies – VE303, soon to begin a Phase 3 registrational trial for prevention of recurrent C. difficile infection, and VE202, in a Phase 2 trial for treatment of ulcerative colitis. Vedanta’s pipeline has been built using the company’s industry-leading product engine for the development of therapies based on defined consortia of bacteria grown from pure clonal cell banks. The product engine, supported by broad foundational intellectual property, includes one of the largest libraries of bacteria isolated from the human microbiome, vast clinical datasets, proprietary capabilities in consortium design, and end-to-end CGMP manufacturing capabilities at commercial launch scale.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构